Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: An Italian prostatic cancer project (P.O.N.CA.P.) study.

F. Boccardo, A. Decensi, D. Guarneri, A. Rubagotti, T. Massa, G. Martorana, C. Giberti, G. B. Cerruti, F. Tani, A. Zanollo, T. Germinale, C. Borzone, F. Perri, E. Usai, L. Santi, L. Giuliani

Research output: Contribution to journalArticle

Abstract

Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treated with the depot formulation of D-TRP-6 LH-RH ('Decapeptyl') for up to 33 months. Serum testosterone (T) levels were significantly reduced to castration levels within 4 weeks and maintained persistently low. Similarly, LH levels were decreased, although they remained in the normal range. Stimulation tests with either Gn-RH or HCG in course of treatment showed the achievement of a complete pituitary desensitization and almost a complete down-regulation of testicular LH receptors. Of 88 patients evaluable for response about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms was obtained without major side effects. These results indicate that the depot formulation of D-TRP-6 LH-RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.

Original languageEnglish
Pages (from-to)243-255
Number of pages13
JournalProstate
Volume11
Issue number3
Publication statusPublished - 1987

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: An Italian prostatic cancer project (P.O.N.CA.P.) study.'. Together they form a unique fingerprint.

  • Cite this

    Boccardo, F., Decensi, A., Guarneri, D., Rubagotti, A., Massa, T., Martorana, G., Giberti, C., Cerruti, G. B., Tani, F., Zanollo, A., Germinale, T., Borzone, C., Perri, F., Usai, E., Santi, L., & Giuliani, L. (1987). Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: An Italian prostatic cancer project (P.O.N.CA.P.) study. Prostate, 11(3), 243-255.